Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry.
Patients with a defect in one of the enzymes of the pyrimidine degradation pathway can be diagnosed by an aberrant excretion profile of the pyrimidine bases and their degradation products in urine (1). For example, in patients with a complete deficiency of dihydropyrimidinase, highly increased concentrations of 5,6-dihydrouracil and 5,6-dihydrothymine and moderately increased concentrations of uracil and thymine can be detected in urine. It has also been suggested that the 5,6-dihydrouracil/ uracil ratio in plasma of patients with cancer is a prognostic indicator for the toxicity of 5-fluorouracil-based chemotherapy (2). In addition, increased concentrations of 5,6-dihydrouridine, a naturally occurring component in prokaryote and eukaryote tRNA, have been found in the urine of cancer patients.
Recently we developed a screening procedure for defects in the pyrimidine degradation pathway that combines reversed-phase HPLC with electrospray ionization tandem mass spectrometry (1). Surprisingly, the analysis of 5,6-dihydrouridine in urine with the chromatographic and MS conditions as described for the pyrimidine bases and their degradation products showed that the presence of this compound interferes with the detection of 5,6-dihydrouracil. An intense multiple-reaction monitoring signal for the transition m/z 115 [right arrow] 73 was observed for 5,6-dihydrouridine, a transition previously selected for the detection of 5,6-dihydrouracil (see Fig. 1, A and B). In the ion source, 5,6-dihydrouridine ([[M + H].sup.+] = m/z 247) is partly degraded to m/z 115, which is identical to the [[M + H].sup.+] ion of dihydrouracil. Because 5,6-dihydrouridine coelutes with dihydrouracil, it contributes substantially to the transition peak attributed to dihydrouracil. The interference of 5,6-dihydrouridine could be eliminated by use of the transition m/z 132 [right arrow] 115 for the detection of dihydrouracil (see Fig. 1, C and D). The selected parent ion [[M + N[H.sub.4]].sup.+] at m/z 132 cannot be produced by 5,6-dihydrouridine; thus, it no longer forms a source of peak contamination. The transition for the internal standard ([[sup.13][C.sub.4],[sup.15][N.sub.2]]-dihydrouracil) was adjusted accordingly.
[FIGURE 1 OMITTED]
The detection limits (defined as a signal-to-noise ratio of 3) for 5,6-dihydrouracil were 2-5 [micro]mol/L and 0.3 [micro]mol/L for urine and plasma, respectively. Table 1 shows the intraassay (within-day) variation and recovery of 5,6-dihydrouracil in urine and plasma. At the detection limit, we observed a relatively large variation for the reproducibility and recovery of 5,6-dihydrouracil in urine and plasma. However, at higher 5,6-dihydrouracil concentrations that were comparable to those found in patients with a dihydropyrimidinase deficiency, we obtained excellent reproducibility and recoveries for urine, urine-soaked filter paper strips, and plasma. Reference values were established for 5,6-dihydrouracil in urine for four different age groups: 0-2 years (n = 45), mean (SD), 7.2 (6.0) [micro]mol/mmol of creatinine (range, 2.0-31 [micro]mol/ mmol of creatinine); 2-6 years (n = 25), 3.0 (1.5) [micro]mol/ mmol of creatinine (range, 1.0-6.0 [micro]mol/mmol of creatinine); 6-10 years (n = 12), 3.8 (3.3) [micro]mol/mmol of creatinine (range, 1.0-11.0 [micro]mol/mmol of creatinine); >10 years (n = 23), 2.0 (1.9) [micro]mol/mmol of creatinine (range, 1.0-10.0 [micro]mol/mmol of creatinine). In plasma, a low concentration of 5,6-dihydrouracil was detected with a mean concentration of 1.3 (0.6) [micro]mol/L (n = 10). Comparable values for 5,6-dihydrouracil have been found in plasma and urine by conventional reversed-phase HPLC (3,4).
In urine from newborns, the mean concentration of 5,6-dihydrouridine is ~40.4 (5.5) [micro]mol/mmol of creatinine (5). Thus, the urinary concentrations of 5,6-dihydrouridine are sixfold higher than the 5,6-dihydrouracil concentrations. Nevertheless, the specific transition of m/z 132 [right arrow] 115 for 5,6-dihydrouracil allows the identification of all pyrimidine bases and their degradation products within one analytical run of 15 min.
(1.) van Lenthe H, van Kuilenburg ABP, Ito T, Bootsma AH, van Cruchten A, Wada Y, et al. Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips. Clin Chem 2000;46:1916-22.
(2.) Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-10.
(3.) Garg MB, Sevester JC, Sakoff JA, Ackland SP. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B 2002;774:223-30.
(4.) Sumi S, Imaeda M, Kidouchi K, Ohba S, Hamajima N, Kodama K, et al. Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am J Med Genet 1998;78:336-40.
(5.) Topp H, Duden R, Schoch G. 5,6-Dihydrouridine: a marker ribonucleoside for determining whole body degradation rates of transfer RNA in man and rats. Clin Chim Acta 1993;218:73-82.
DOI : 10.1373/clinchem.2003.026229
Andre B.P. van Kuilenburg, * Henk van Lenthe, Arno van Cruchten, and Willem Kulik (Academic Medical Center, University of Amsterdam, Emma Children's Hospital and Department of Clinical Chemistry, PO Box 22700, 1100 DE Amsterdam, The Netherlands; * address correspondence to this author at: Academic Medical Center, Laboratory for Genetic Metabolic Diseases, FO-224, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; fax 31-206962596, e-mail a.b.vanKuilenburg@amc.uva.nl)
Table 1. Intraassay variation and recovery of 5,6-dihydrouracil in urine, filter paper extracts, and plasma. (a) Intraassay variation (n = 10) [micro]mol/L CV, % Urine Blank 1.0 (0.9) 89 Low (x) 11.7 (1.0) 8 Medium (d) 100 (4) 4 High (e) 1042 (50) 5 Urine-filter paper Blank ND (f) Low (x) 11.8 (2.9) 25 Medium (d) 102 (7) 7 High (e) 1016 (58) 6 Plasma Blank 1.2 (0.3) 22 Low (x) 2.1 (0.4) 21 Medium (d) 11 (1) 9 High (e) 102 (3) 3 Recoveries (b) [micro]mol/L Recovery, % CV, % Urine Blank 8.8 (5.3) 60 Low (x) 103 (31) 31 Medium (d) 97 (6) 6 High (e) 103 (9) 9 Urine-filter paper Blank 12 (8.7) 73 Low (x) 81 (42) 51 Medium (d) 89 (9) 10 High (e) 96 (12) 12 Plasma Blank 1.3 (0.6) 46 Low (x) 101 (83) 82 Medium (d) 103 (7) 7 High (e) 101 (6) 6 (a) Values in parentheses are the SD. (b) Recoveries in 10 different urine and plasma samples. (c) Supplemented with 1 mol/L (plasma) or 10 mol/L (urine). (d) Supplemented with 10 mol/L (plasma) or 100 mol/L (urine). (e) Supplemented with 100 mol/L (plasma) or 1000 mol/L (urine). (f) ND, not detectable ( 2 mol/L).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||van Kuilenburg, Andre B.P.; van Lenthe, Henk; van Cruchten, Arno; Kulik, Willem|
|Date:||Jan 1, 2004|
|Previous Article:||Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma.|
|Next Article:||Vitamin [B.sub.12] status in the elderly as judged by available biochemical markers.|